FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048559248> ?p ?o ?g. }

• W3048559248 endingPage "2255" @default.
• W3048559248 startingPage "2255" @default.
• W3048559248 abstract "To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after a median of 4 cycles and lasted for a median of 11 months (range 0.9 to 120 months). With a median follow-up of 22 months (range: 1 to 122 months), the 2-year survival rate was 38% ± 9%, including 17 patients with ongoing remission for >5 years. Based on results from multivariate analyses, molecular relapse and time to relapse were integrated into a score, clearly dividing patients into 3 subgroups with CR rates of 71%, 39%, and 29%; and 2-year survival rates of 64%, 38%, and 27%, respectively. In the subgroup of MDS and secondary AML, receiving upfront transplantation was associated with superior response and survival, and therefore pretransplant strategy was integrated together with relapse type into a MDS–sAML-specific score. Overall, Aza enables meaningful responses and long-term survival, which is a predictable with a simple-to-use scoring system." @default.
• W3048559248 created "2020-08-18" @default.
• W3048559248 creator A5000503465 @default.
• W3048559248 creator A5001433615 @default.
• W3048559248 creator A5004460743 @default.
• W3048559248 creator A5005172825 @default.
• W3048559248 creator A5028574694 @default.
• W3048559248 creator A5033690796 @default.
• W3048559248 creator A5048355658 @default.
• W3048559248 creator A5050623124 @default.
• W3048559248 creator A5061663931 @default.
• W3048559248 creator A5068674008 @default.
• W3048559248 creator A5091012599 @default.
• W3048559248 date "2020-08-12" @default.
• W3048559248 modified "2023-10-14" @default.
• W3048559248 title "Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation" @default.
• W3048559248 cites W1796660362 @default.
• W3048559248 cites W1993775778 @default.
• W3048559248 cites W2004498221 @default.
• W3048559248 cites W2021378114 @default.
• W3048559248 cites W2032685836 @default.
• W3048559248 cites W2040073738 @default.
• W3048559248 cites W2050519979 @default.
• W3048559248 cites W2053278212 @default.
• W3048559248 cites W2059380567 @default.
• W3048559248 cites W2066124347 @default.
• W3048559248 cites W2074326274 @default.
• W3048559248 cites W2129510594 @default.
• W3048559248 cites W2133384656 @default.
• W3048559248 cites W2152197116 @default.
• W3048559248 cites W2326726820 @default.
• W3048559248 cites W2339658711 @default.
• W3048559248 cites W2340869536 @default.
• W3048559248 cites W2379365975 @default.
• W3048559248 cites W2424060136 @default.
• W3048559248 cites W2558410797 @default.
• W3048559248 cites W2559449184 @default.
• W3048559248 cites W2559537906 @default.
• W3048559248 cites W2575545223 @default.
• W3048559248 cites W2618073389 @default.
• W3048559248 cites W2765151185 @default.
• W3048559248 cites W2770466614 @default.
• W3048559248 cites W2770885738 @default.
• W3048559248 cites W2800366296 @default.
• W3048559248 cites W2901332394 @default.
• W3048559248 cites W2908841748 @default.
• W3048559248 cites W2909224113 @default.
• W3048559248 cites W2912484083 @default.
• W3048559248 cites W2922405080 @default.
• W3048559248 cites W2923556687 @default.
• W3048559248 cites W2963453457 @default.
• W3048559248 cites W2982353618 @default.
• W3048559248 cites W2982808575 @default.
• W3048559248 cites W3003528460 @default.
• W3048559248 cites W3014928753 @default.
• W3048559248 cites W3022828968 @default.
• W3048559248 doi "https://doi.org/10.3390/cancers12082255" @default.
• W3048559248 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7464210" @default.
• W3048559248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32806572" @default.
• W3048559248 hasPublicationYear "2020" @default.
• W3048559248 type Work @default.
• W3048559248 sameAs 3048559248 @default.
• W3048559248 citedByCount "13" @default.
• W3048559248 countsByYear W30485592482020 @default.
• W3048559248 countsByYear W30485592482021 @default.
• W3048559248 countsByYear W30485592482022 @default.
• W3048559248 countsByYear W30485592482023 @default.
• W3048559248 crossrefType "journal-article" @default.
• W3048559248 hasAuthorship W3048559248A5000503465 @default.
• W3048559248 hasAuthorship W3048559248A5001433615 @default.
• W3048559248 hasAuthorship W3048559248A5004460743 @default.
• W3048559248 hasAuthorship W3048559248A5005172825 @default.
• W3048559248 hasAuthorship W3048559248A5028574694 @default.
• W3048559248 hasAuthorship W3048559248A5033690796 @default.
• W3048559248 hasAuthorship W3048559248A5048355658 @default.
• W3048559248 hasAuthorship W3048559248A5050623124 @default.
• W3048559248 hasAuthorship W3048559248A5061663931 @default.
• W3048559248 hasAuthorship W3048559248A5068674008 @default.
• W3048559248 hasAuthorship W3048559248A5091012599 @default.
• W3048559248 hasBestOaLocation W30485592481 @default.
• W3048559248 hasConcept C104317684 @default.
• W3048559248 hasConcept C126322002 @default.
• W3048559248 hasConcept C143998085 @default.
• W3048559248 hasConcept C150194340 @default.
• W3048559248 hasConcept C190727270 @default.
• W3048559248 hasConcept C2776239401 @default.
• W3048559248 hasConcept C2776694085 @default.
• W3048559248 hasConcept C2777408962 @default.
• W3048559248 hasConcept C2778729363 @default.
• W3048559248 hasConcept C2779282312 @default.
• W3048559248 hasConcept C2779695342 @default.
• W3048559248 hasConcept C2780007613 @default.
• W3048559248 hasConcept C2780775027 @default.
• W3048559248 hasConcept C2780817109 @default.
• W3048559248 hasConcept C28328180 @default.
• W3048559248 hasConcept C2911091166 @default.
• W3048559248 hasConcept C3018657049 @default.
• W3048559248 hasConcept C54355233 @default.

• next